Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To develop bio-nanoparticle-based siRNA therapeutic vaccines, using Chimigen Vaccine Platform for Hepatitis B (HBV) and Hepatitis C (HCV) infections
Subscribe to our email newsletter
ViRexx has received a contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This 14-month project will focus on the development of bio-nanoparticle-based siRNA therapeutic vaccines, using Chimigen Vaccine Platform for Hepatitis B (HBV) and Hepatitis C (HCV) infections.
ViRexx is currently developing a Chimigen HBV Therapeutic Vaccine to address the 370 million chronic carriers of Hepatitis B virus worldwide, who are poorly served by existing therapies.
Additionally, the company is also developing Chimigen HCV Therapeutic vaccines, as well as bio-nanoparticle-based siRNA therapeutic vaccines for both HBV and HCV infections.
Jonathan Ross Goodman, president and CEO of Paladin, said: The acquisition of ViRexx gave us a very promising technology in Chimigen Platform. We are excited to be working with NRC-IRAP on the development of this important technology platform.